Artykuły w czasopismach na temat „Drug-sparing regimen”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Drug-sparing regimen”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Rosa, Rossana, Jose F. Suarez, Marco A. Lorio, Michele I. Morris, Lilian M. Abbo, Jacques Simkins, Giselle Guerra i in. "Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases". F1000Research 5 (21.12.2016): 2893. http://dx.doi.org/10.12688/f1000research.10414.1.
Pełny tekst źródłaDutta, Noton K., Abdullah Alsultan, Thomas J. Gniadek, Deborah A. Belchis, Michael L. Pinn, Khisimuzi E. Mdluli, Eric L. Nuermberger, Charles A. Peloquin i Petros C. Karakousis. "Potent Rifamycin-Sparing Regimen Cures Guinea Pig Tuberculosis as Rapidly as the Standard Regimen". Antimicrobial Agents and Chemotherapy 57, nr 8 (3.06.2013): 3910–16. http://dx.doi.org/10.1128/aac.00761-13.
Pełny tekst źródłaRuzicka, Daniel J., Mayuko Kamakura, Naho Kuroishi, Nobuyuki Oshima, Miyuki Yamatani, Jingbo Yi, Bruce Crawford, Kunihisa Tsukada i Shinichi Oka. "Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan". PLOS ONE 17, nr 6 (14.06.2022): e0269779. http://dx.doi.org/10.1371/journal.pone.0269779.
Pełny tekst źródłaMaggiolo, Franco, Nicola Gianotti, Laura Comi, Elisa Di Filippo, Laura Fumagalli, Silvia Nozza, Laura Galli, Daniela Valenti, Marco Rizzi i Antonella Castagna. "Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial". Antiviral Therapy 26, nr 3-5 (maj 2021): 51–57. http://dx.doi.org/10.1177/13596535211042226.
Pełny tekst źródłaSleeper, Rebecca B. "Antipsychotic Dose-Sparing Effect with Addition of Memantine". Annals of Pharmacotherapy 39, nr 9 (wrzesień 2005): 1573–76. http://dx.doi.org/10.1345/aph.1g207.
Pełny tekst źródłaTiberi, Simon, Marie-Christine Payen, Giovanni Sotgiu, Lia D'Ambrosio, Valentina Alarcon Guizado, Jan Willem Alffenaar, Marcos Abdo Arbex i in. "Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB". European Respiratory Journal 47, nr 4 (10.03.2016): 1235–43. http://dx.doi.org/10.1183/13993003.02146-2015.
Pełny tekst źródłaFischl, Margaret A., Ann C. Collier, A. Lisa Mukherjee, Judith E. Feinberg, Lisa M. Demeter, Pablo Tebas, Marina Giuliano i in. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen". AIDS 21, nr 3 (styczeń 2007): 325–33. http://dx.doi.org/10.1097/qad.0b013e328011ddfa.
Pełny tekst źródłaKaroney, Mercy Jelagat, Mathew Kirtptonui Koech, Evangeline Wawira Njiru i Willis Dixon Owino Ong’or. "Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya". PLOS ONE 17, nr 9 (15.09.2022): e0273183. http://dx.doi.org/10.1371/journal.pone.0273183.
Pełny tekst źródłaStürmer, Martin, Schlomo Staszewski i Hans Wilhelm Doerr. "Quadruple Nucleoside Therapy with Zidovudine, Lamivudine, Abacavir and Tenofovir in the Treatment of HIV". Antiviral Therapy 12, nr 5 (lipiec 2007): 695–704. http://dx.doi.org/10.1177/135965350701200514.
Pełny tekst źródłaKovalskaya, Galina N., Dina Y. Zhukova i Ekaterina N. Mikhalevich. "Interaction of Drugs Used for the Treatment of Cardiovascular Diseases". Acta Biomedica Scientifica 4, nr 1 (4.04.2019): 36–42. http://dx.doi.org/10.29413/abs.2019-4.1.6.
Pełny tekst źródłaDwyer, Dominic E., Cassy Workman, Gillian Hales, Janaki Amin, David Cooper, John Miller i Sean Emery. "Enfuvirtide in HIV-1-Infected Individuals Changing Therapy to A Nucleoside Reverse Transcriptase Inhibitor Sparing Regimen: The Alliance Study". Antiviral Therapy 11, nr 4 (1.05.2005): 409–19. http://dx.doi.org/10.1177/135965350601100406.
Pełny tekst źródłaRabin, Bradford C., Kristina Reid, Tian-Zhi Guo, Eva Gustafsson, Chousheng Zhang i Mervyn Maze. "Sympatholytic and Minimum Anesthetic Concentration-sparing Responses are Preserved in Rats Rendered Tolerant to the Hypnotic and Analgesic Action of Dexmedetomidine, a Selective α2-adrenergic Agonist". Anesthesiology 85, nr 3 (1.09.1996): 565–73. http://dx.doi.org/10.1097/00000542-199609000-00016.
Pełny tekst źródłaLewis, David A. "New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance". Sexual Health 16, nr 5 (2019): 449. http://dx.doi.org/10.1071/sh19034.
Pełny tekst źródłaAutar, Reshma S., Mark A. Boyd, Ferdinand WMN Wit, Kiat Ruxrungtham, Jongkol Sankote, Joep MA Lange, David A. Cooper, Praphan Phanuphak, David M. Burger i Peter Reiss. "Relationships between Drug Exposure, Changes in Metabolic Parameters and Body Fat in HIV-Infected Patients Switched to a Nucleoside Sparing Regimen". Antiviral Therapy 12, nr 8 (listopad 2007): 1265–72. http://dx.doi.org/10.1177/135965350701200813.
Pełny tekst źródłaBrugière, Olivier, Alexandre Vallée, Quentin Raimbourg, Marie-Noelle Peraldi, Sylvie Colin de Verdière, Laurence Beaumont, Abdulmonem Hamid i in. "Conversion to belatacept after lung transplantation: Report of 10 cases". PLOS ONE 18, nr 3 (15.03.2023): e0281492. http://dx.doi.org/10.1371/journal.pone.0281492.
Pełny tekst źródłaSultan, Mamoona, Adeena Khan, Syed Shahid Habib i Dheyab Abdulsalam. "Unique clinical spectrum with distinguishing diagnostic features in Vogt-Koyanagi-Harada syndrome". BMJ Case Reports 12, nr 12 (grudzień 2019): e231397. http://dx.doi.org/10.1136/bcr-2019-231397.
Pełny tekst źródłaDelyagin, Wassili M., i Inna V. Lukjanova. "Heart failure in children and adolescents (high yield topics for primary care pediatrician)". Pediatrics. Consilium Medicum, nr 3 (15.09.2021): 277–84. http://dx.doi.org/10.26442/26586630.2021.3.200998.
Pełny tekst źródłaHong, H., D. W. Dowdy, K. E. Dooley, H. W. Francis, C. Budhathoki, H.-R. Han i J. E. Farley. "Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose". International Journal of Tuberculosis and Lung Disease 24, nr 1 (1.01.2020): 65–72. http://dx.doi.org/10.5588/ijtld.19.0062.
Pełny tekst źródłaKast, Richard E., Marc-Eric Halatsch i Rafael Rosell. "OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs". Cells 10, nr 5 (10.05.2021): 1148. http://dx.doi.org/10.3390/cells10051148.
Pełny tekst źródłaTotiger, Tulasigeri M., Anirban Ghoshal, Jenna Zabroski, Anya Sondhi, Saanvi Bucha, Jacob Jahn, Yangbo Feng i Justin Taylor. "Targeted Therapy Development in Acute Myeloid Leukemia". Biomedicines 11, nr 2 (20.02.2023): 641. http://dx.doi.org/10.3390/biomedicines11020641.
Pełny tekst źródłaEisbruch, Avraham, John M. Robertson, Carolyn M. Johnston, Joseph Tworek, Kevin R. Reynolds, James A. Roberts i Theodore S. Lawrence. "Bromodeoxyuridine Alternating With Radiation for Advanced Uterine Cervix Cancer: A Phase I and Drug Incorporation Study". Journal of Clinical Oncology 17, nr 1 (styczeń 1999): 31. http://dx.doi.org/10.1200/jco.1999.17.1.31.
Pełny tekst źródłaKim, You Sun. "Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators". Journal of the Korean Medical Association 64, nr 9 (10.09.2021): 596–604. http://dx.doi.org/10.5124/jkma.2021.64.9.596.
Pełny tekst źródłaSher, Taimur, Kena C. Miller, Sikander Ailawadhi, Debbie Manfredi, Margaret Wood, Wei Tan, Gregory Wilding i in. "Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study." Blood 114, nr 22 (20.11.2009): 618. http://dx.doi.org/10.1182/blood.v114.22.618.618.
Pełny tekst źródłaLaw, Lisa Y., Ryan Stevenson, Gwendolyn Ho, Bijay Nair, Asakura Laura i Antoine Sayegh. "Venetoclax-Based Regimen for Treatment of Patients with Acute Myeloid Leukemia in Community Based Practices". Blood 134, Supplement_1 (13.11.2019): 5081. http://dx.doi.org/10.1182/blood-2019-121816.
Pełny tekst źródłaHorvath, Lena, i Andreas Pircher. "ASCO 2020 non-small lung cancer (NSCLC) personal highlights". memo - Magazine of European Medical Oncology 14, nr 1 (13.01.2021): 66–69. http://dx.doi.org/10.1007/s12254-020-00673-2.
Pełny tekst źródłaFinn, Jonathan D., Patricia Favaro, J. Fraser Wright, Federico Mingozzi, Katherine A. High i Valder R. Arruda. "Rabbit Anti-Thymocyte Globulin (rATG) Administrated Concomitantly with Liver Delivery of AAV2-hFIX Can Promote Inhibitor Formation In Rhesus Macaques." Blood 116, nr 21 (19.11.2010): 3765. http://dx.doi.org/10.1182/blood.v116.21.3765.3765.
Pełny tekst źródłaDybkær, Karen, Hanne Due, Rasmus Froberg Brøndum, Ken H. Young i Martin Bøgsted. "Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP". Blood 134, Supplement_1 (13.11.2019): 1623. http://dx.doi.org/10.1182/blood-2019-122351.
Pełny tekst źródłaSoon, Gaik H., Ping Shen, Eu-Leong Yong, Paul Pham, Charles Flexner i Lawrence Lee. "Pharmacokinetics of Darunavir at 900 Milligrams and Ritonavir at 100 Milligrams Once Daily when Coadministered with Efavirenz at 600 Milligrams Once Daily in Healthy Volunteers". Antimicrobial Agents and Chemotherapy 54, nr 7 (12.04.2010): 2775–80. http://dx.doi.org/10.1128/aac.01564-09.
Pełny tekst źródłaNg, Loke, Yeo, Chng i Tan. "A Meta-Analysis of the Utility of Preoperative Intravenous Paracetamol for Post-Caesarean Analgesia". Medicina 55, nr 8 (31.07.2019): 424. http://dx.doi.org/10.3390/medicina55080424.
Pełny tekst źródłaJeny, Florence, Hilario Nunes i Dominique Valeyre. "Current Medical Therapy for Sarcoidosis". Seminars in Respiratory and Critical Care Medicine 38, nr 04 (27.07.2017): 523–31. http://dx.doi.org/10.1055/s-0037-1604032.
Pełny tekst źródłaS., Sivakumar, i Banupriya K. "Monitoring of adverse drug reactions caused by methotrexate at the dermatology department of a tertiary care centre". International Journal of Research in Dermatology 3, nr 3 (24.08.2017): 389. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20173078.
Pełny tekst źródłaLauretti, Gabriela R., Izabel C. P. R. Lima, Marlene P. Reis, Wiliam A. Prado i Newton L. Pereira. "Oral Ketamine and Transdermal Nitroglycerin as Analgesic Adjuvants to Oral Morphine Therapy for Cancer Pain Management". Anesthesiology 90, nr 6 (1.06.1999): 1528–33. http://dx.doi.org/10.1097/00000542-199906000-00005.
Pełny tekst źródłaGandola, L., M. Nantron, A. Marchianò, A. Pession, P. Indolfi, A. Di Cataldo, P. Collini, G. Arcamone, F. Fossati Bellani i F. Spreafico. "Outcome in stage IV Wilms tumor treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials". Journal of Clinical Oncology 27, nr 15_suppl (20.05.2009): 10031. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.10031.
Pełny tekst źródłaMironov, S. P., M. B. Cykunov, G. M. Burmakova i S. V. Andreev. "Lumbosacral pain in athletes and ballet dancers: spondylolysis and spondylolisthesis. Conservative treatment". N.N. Priorov Journal of Traumatology and Orthopedics 27, nr 1 (1.04.2020): 11–18. http://dx.doi.org/10.17816/vto202027111-18.
Pełny tekst źródłaPei, Xin-Yan, Michael W. Sanderson, Leena E. Youssefian, Jessica Felthousen, Lora B. Kramer, Yun Dai i Steven Grant. "Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism". Blood 124, nr 21 (6.12.2014): 4763. http://dx.doi.org/10.1182/blood.v124.21.4763.4763.
Pełny tekst źródłaWinkler, K., G. Beron, G. Delling, U. Heise, H. Kabisch, C. Purfürst, J. Berger, J. Ritter, H. Jürgens i V. Gerein. "Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response." Journal of Clinical Oncology 6, nr 2 (luty 1988): 329–37. http://dx.doi.org/10.1200/jco.1988.6.2.329.
Pełny tekst źródłavan der Lee, Miranda M. C., Tanja van Achterberg, Kaylee Hersmus, Annet Brouwers-Vos, Monique van der Vleuten, Maurien Pruis, Wendy Kappers i in. "Abstract 3129: BYON4413, an in vivo active CD123-targeting antibody-drug conjugate, combines effectively with azacitidine and venetoclax in acute myeloid leukemia cell lines". Cancer Research 84, nr 6_Supplement (22.03.2024): 3129. http://dx.doi.org/10.1158/1538-7445.am2024-3129.
Pełny tekst źródłaNormant, Emmanuel, Marcelo Lima Ribeiro, Nuria Profitos-Peleja, Pedro Blecua, Diana Reyes-Garau, Juliana Carvalho Santos, Marc Armengol, Miranda Fernández-Serrano, Hari P. Miskin i Gael Roue. "The Ublituximab-Umbralisib (U2) Drug Regimen Potentiates the Activity of the Novel CD47-CD19 Bispecific Antibody, TG-1801, through the Activation of the G Protein-Coupled Receptor EBI2/GPR183". Blood 138, Supplement 1 (5.11.2021): 1196. http://dx.doi.org/10.1182/blood-2021-150570.
Pełny tekst źródłaLiguori, Nicholas R., Ashley Fss Uruchurtu, Young Lee, Leiqing Zhang, Abbas Abbas, Varun Prabhu, Lanlan Zhou, Christopher J. Azzoli i Wafik S. El-Deiry. "Abstract 4064: Synergistic activity of Lurbinectidin plus ONC201 in SCLC is associated with ATF4, CHOP and pChk1 induction". Cancer Research 82, nr 12_Supplement (15.06.2022): 4064. http://dx.doi.org/10.1158/1538-7445.am2022-4064.
Pełny tekst źródłaLu, Norman, Patricia Soulard, Kay Li, Heather Sadlish, Chris Yates, Xiubin Gu, Ibrahim Kays i in. "Abstract 3306: RGT-M001, a first-in-class small molecule mRNA degrader of the oncogenic transcription factor c-Myb, demonstrated remarkable single agent anti-tumor efficacy in cancer patient-derived xenograft model". Cancer Research 84, nr 6_Supplement (22.03.2024): 3306. http://dx.doi.org/10.1158/1538-7445.am2024-3306.
Pełny tekst źródłaDeisher, Theresa, Margaret Taylor, Arya Ashok, Peter Jarzyna, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin i Vaishnavi Parthasarathy. "AVM0703, a New Treatment Option for Lymphoma Patients". Blood 134, Supplement_1 (13.11.2019): 5308. http://dx.doi.org/10.1182/blood-2019-128812.
Pełny tekst źródłaHamilton, Erika Paige, Manish R. Patel, Jordi Rodon, David S. Hong, Alison M. Schram, Pasi A. Janne, Patricia LoRusso i in. "Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): TPS3665. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps3665.
Pełny tekst źródładiCapua Siegel, David Samuel, Thomas Martin, Michael Wang, Ravi Vij, Andrzej J. Jakubowiak, Sundar Jagannath, Sagar Lonial i in. "Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)". Blood 116, nr 21 (19.11.2010): 985. http://dx.doi.org/10.1182/blood.v116.21.985.985.
Pełny tekst źródłaMarcelin, A. G., B. Visseaux, M. Wirden, L. Morand-Joubert, C. Soulie, C. Charpentier, B. Masquelier, D. Descamps i V. Calvez. "NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment". Journal of Global Antimicrobial Resistance 2, nr 2 (czerwiec 2014): 103–6. http://dx.doi.org/10.1016/j.jgar.2013.12.001.
Pełny tekst źródłaDai, Yun, Shuang Chen, Xin-Yan Pei, Viswanathan Ramakrishnan, Michael Wang, Robert Orlowski, Paul Dent i Steven Grant. "Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism." Blood 114, nr 22 (20.11.2009): 297. http://dx.doi.org/10.1182/blood.v114.22.297.297.
Pełny tekst źródłaHoward, Caleigh, Shu Wiley, Wenzhao Dong, Andrea Mendiola, Veronica Partridge, Sara LeMar, Paul Amador i in. "Abstract 335: c-KIT targeted ETBs for cancer therapy and HSC transplant conditioning". Cancer Research 82, nr 12_Supplement (15.06.2022): 335. http://dx.doi.org/10.1158/1538-7445.am2022-335.
Pełny tekst źródłaPuoti, Massimo, Alessandro Cozzi-Lepri, Fausto Ancarani, Raffaele Bruno, Silvia Ambu, Teresa Ferraro, Paolo Tundo i in. "The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?" Antiviral Therapy 9, nr 5 (lipiec 2004): 811–17. http://dx.doi.org/10.1177/135965350400900506.
Pełny tekst źródłaTreon, Steven P., Kirsten Meid, Joshua Gustine, Christopher J. Patterson, Jeffrey V. Matous, Irene M. Ghobrial i Jorge J. Castillo. "Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia". Blood 126, nr 23 (3.12.2015): 1833. http://dx.doi.org/10.1182/blood.v126.23.1833.1833.
Pełny tekst źródłaYoshizawa, Toshio, Tomoko Yasuhiro, Hideyuki Honda i Kazuhito Kawabata. "ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model". Blood 124, nr 21 (6.12.2014): 4502. http://dx.doi.org/10.1182/blood.v124.21.4502.4502.
Pełny tekst źródłaWang, C., H. Song, Z. Yu i M. Quan. "AB1009 THE EFFICACY OF TOCILIZUMAB ON THE TREATMENT OF TAKAYASU ARTERITIS IN CHINESE CHILDREN". Annals of the Rheumatic Diseases 79, Suppl 1 (czerwiec 2020): 1798.2–1798. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5778.
Pełny tekst źródła